FDA To Look At Risks Of J&J, Amgen Anemia Drugs

Law360, New York (January 7, 2010, 1:56 PM EST) -- The U.S. Food and Drug Administration has said that it likely will take another look at drugs made by Johnson & Johnson and Amgen Inc. in light of a clinical study that raised questions about the drugs' safety when treating anemia from chronic kidney disease.

In commentary published on the New England Journal of Medicine's Web site on Wednesday, physicians with the FDA said trials related to erythropoiesis-stimulating agents did not yield “convincing evidence of any consistent quality-of-life benefit that would appear to outweigh the increased...
To view the full article, register now.